2.
晚期胃癌患者生存的单因素分析
Univariate analysis of survival of patients with advanced gastric cancer
| Variables | P | HR | 95%CI | |
| Lower-bound | Upper-bound | |||
| *P < 0.05; **P < 0.01; ***P < 0.001. | ||||
| Gender (M/F) | 0.208 | 1.327 | 0.854 | 2.060 |
| Age (years, ≤65 vs >65) | 0.688 | 1.114 | 0.658 | 1.886 |
| Pathological type | ||||
| Adenocarcinoma | Reference | |||
| Signet-ring cell carcinoma | 0.765 | 0.921 | 0.536 | 1.582 |
| Unknown | 0.272 | 0.518 | 0.160 | 1.672 |
| Differentiation degree | ||||
| Poor differentiation | Reference | |||
| Middle-low differentiation | 0.940 | 0.976 | 0.521 | 1.830 |
| Middle differentiation | 0.479 | 0.774 | 0.382 | 1.571 |
| Middle to well differentiation | 0.998 | 0.998 | 0.242 | 4.112 |
| Unknown | 0.205 | 0.550 | 0.218 | 1.386 |
| Lauren type | ||||
| Intestinal type | Reference | |||
| Diffused type | 0.326 | 1.390 | 0.721 | 2.679 |
| Mixed type | 0.771 | 1.119 | 0.525 | 2.382 |
| Unknown | 0.053 | 1.936 | 0.993 | 3.776 |
| MSI status | ||||
| pMMR | Reference | |||
| dMMR | 0.214 | 2.272 | 0.622 | 8.293 |
| Unknown | 0.450 | 1.293 | 0.664 | 2.519 |
| Her-2 status | ||||
| Negative | Reference | |||
| Positive | 0.210 | 0.697 | 0.396 | 1.225 |
| Unknown | 0.258 | 1.386 | 0.788 | 2.438 |
| Liver metastasis (yes vs no) | 0.436 | 1.232 | 0.729 | 2.08 |
| Peritoneal metastasis (yes vs no) | 0.169 | 1.365 | 0.876 | 2.127 |
| Retroperitoneal lymph node metastases (yes vs no) | 0.989 | 1.004 | 0.532 | 1.897 |
| Site of metastasis (≤2 vs＞2) | 0.031* | 0.57 | 0.342 | 0.948 |
| First-line efficacy evaluation ORR (yes vs no) | 0.473 | 0.834 | 0.507 | 1.37 |
| First-line efficacy evaluation DCR (yes vs no) | 0.050* | 0.531 | 0.282 | 1 |
| Treatment regimens | ||||
| Only first-line | Reference | |||
| First- and second-line | 0.034* | 2.037 | 1.056 | 3.926 |
| Third-line or further treatment | 0.907 | 0.965 | 0.531 | 1.753 |
| The PFS time of first-line (≤7 vs >7 m) | 0.000*** | 4.518 | 2.697 | 7.569 |
| First-line surgery (yes vs no) | 0.007** | 0.386 | 0.193 | 0.773 |